Is AURA or KRRO more profitable?

Aura Biosciences has a net margin of 0.00% compared to Korro Bio's net margin of -1,834.48%. Aura Biosciences' return on equity of -73.18% beat Korro Bio's return on equity. Company Net Margins Return on Equity Return on Assets Aura Biosciences N/A -73.18% -62.00% Korro Bio -1,834.48% -114.26% -68.57%

Does the media prefer AURA or KRRO?

In the previous week, Korro Bio had 1 more articles in the media than Aura Biosciences. MarketBeat recorded 7 mentions for Korro Bio and 6 mentions for Aura Biosciences. Aura Biosciences' average media sentiment score of 1.77 beat Korro Bio's score of 0.77 indicating that Aura Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Aura Biosciences 5 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Korro Bio 3 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is KRRO or STTK more profitable?

Shattuck Labs has a net margin of 0.00% compared to Korro Bio's net margin of -1,834.48%. Shattuck Labs' return on equity of -43.57% beat Korro Bio's return on equity. Company Net Margins Return on Equity Return on Assets Korro Bio -1,834.48% -114.26% -68.57% Shattuck Labs N/A -43.57% -40.90%

Does the media prefer KRRO or STTK?

In the previous week, Shattuck Labs had 3 more articles in the media than Korro Bio. MarketBeat recorded 10 mentions for Shattuck Labs and 7 mentions for Korro Bio. Shattuck Labs' average media sentiment score of 1.07 beat Korro Bio's score of 0.77 indicating that Shattuck Labs is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Korro Bio 3 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Shattuck Labs 3 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor ALLO or KRRO?

In the previous week, Allogene Therapeutics had 6 more articles in the media than Korro Bio. MarketBeat recorded 13 mentions for Allogene Therapeutics and 7 mentions for Korro Bio. Allogene Therapeutics' average media sentiment score of 0.92 beat Korro Bio's score of 0.77 indicating that Allogene Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Allogene Therapeutics 6 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Korro Bio 3 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer MNPR or KRRO?

In the previous week, Monopar Therapeutics and Monopar Therapeutics both had 7 articles in the media. Korro Bio's average media sentiment score of 0.77 beat Monopar Therapeutics' score of 0.56 indicating that Korro Bio is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Monopar Therapeutics 4 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Korro Bio 3 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Korro Bio (KRRO) Competitors

$12.57 -0.34 (-2.63%)

As of 11:22 AM Eastern

Compare

KRRO vs. AURA, STTK, BBOT, ALLO, and MNPR

Should you buy Korro Bio stock or one of its competitors? Korro Bio's main competitors and comparable companies include Aura Biosciences (AURA), Shattuck Labs (STTK), BridgeBio Oncology Therapeutics (BBOT), Allogene Therapeutics (ALLO), and Monopar Therapeutics (MNPR). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Korro Bio compare to Aura Biosciences?

Aura Biosciences (NASDAQ:AURA) and Korro Bio (NASDAQ:KRRO) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, analyst recommendations, risk, institutional ownership, media sentiment, valuation, dividends and profitability.

Aura Biosciences has a beta of 0.4, meaning that its stock price is 60% less volatile than the broader market. Comparatively, Korro Bio has a beta of 3.04, meaning that its stock price is 204% more volatile than the broader market.

Aura Biosciences has higher earnings, but lower revenue than Korro Bio. Aura Biosciences is trading at a lower price-to-earnings ratio than Korro Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aura Biosciences	N/A	N/A	-$106.19M	-$1.75	N/A
Korro Bio	$6.39M	28.98	-$117.26M	-$10.00	N/A

In the previous week, Korro Bio had 1 more articles in the media than Aura Biosciences. MarketBeat recorded 7 mentions for Korro Bio and 6 mentions for Aura Biosciences. Aura Biosciences' average media sentiment score of 1.77 beat Korro Bio's score of 0.77 indicating that Aura Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Aura Biosciences	5 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Korro Bio	3 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Aura Biosciences presently has a consensus price target of $17.50, suggesting a potential upside of 144.45%. Korro Bio has a consensus price target of $16.71, suggesting a potential upside of 32.97%. Given Aura Biosciences' higher possible upside, equities analysts clearly believe Aura Biosciences is more favorable than Korro Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aura Biosciences	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Korro Bio	1 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	3 Strong Buy rating(s)	2.92

96.8% of Aura Biosciences shares are held by institutional investors. Comparatively, 13.2% of Korro Bio shares are held by institutional investors. 1.9% of Aura Biosciences shares are held by insiders. Comparatively, 4.8% of Korro Bio shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Aura Biosciences has a net margin of 0.00% compared to Korro Bio's net margin of -1,834.48%. Aura Biosciences' return on equity of -73.18% beat Korro Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aura Biosciences	N/A	-73.18%	-62.00%
Korro Bio	-1,834.48%	-114.26%	-68.57%

Summary

Aura Biosciences and Korro Bio tied by winning 8 of the 16 factors compared between the two stocks.

How does Korro Bio compare to Shattuck Labs?

Korro Bio (NASDAQ:KRRO) and Shattuck Labs (NASDAQ:STTK) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, earnings, analyst recommendations, risk, valuation and media sentiment.

In the previous week, Shattuck Labs had 3 more articles in the media than Korro Bio. MarketBeat recorded 10 mentions for Shattuck Labs and 7 mentions for Korro Bio. Shattuck Labs' average media sentiment score of 1.07 beat Korro Bio's score of 0.77 indicating that Shattuck Labs is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Korro Bio	3 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Shattuck Labs	3 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Korro Bio presently has a consensus price target of $16.71, indicating a potential upside of 32.97%. Shattuck Labs has a consensus price target of $12.78, indicating a potential upside of 85.16%. Given Shattuck Labs' stronger consensus rating and higher probable upside, analysts plainly believe Shattuck Labs is more favorable than Korro Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Korro Bio	1 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	3 Strong Buy rating(s)	2.92
Shattuck Labs	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	2 Strong Buy rating(s)	3.00

Shattuck Labs has lower revenue, but higher earnings than Korro Bio. Shattuck Labs is trading at a lower price-to-earnings ratio than Korro Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Korro Bio	$6.39M	28.98	-$117.26M	-$10.00	N/A
Shattuck Labs	$1M	692.58	-$48.81M	-$0.51	N/A

Shattuck Labs has a net margin of 0.00% compared to Korro Bio's net margin of -1,834.48%. Shattuck Labs' return on equity of -43.57% beat Korro Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Korro Bio	-1,834.48%	-114.26%	-68.57%
Shattuck Labs	N/A	-43.57%	-40.90%

13.2% of Korro Bio shares are held by institutional investors. Comparatively, 58.7% of Shattuck Labs shares are held by institutional investors. 4.8% of Korro Bio shares are held by insiders. Comparatively, 8.8% of Shattuck Labs shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Korro Bio has a beta of 3.04, suggesting that its stock price is 204% more volatile than the broader market. Comparatively, Shattuck Labs has a beta of 1.08, suggesting that its stock price is 8% more volatile than the broader market.

Summary

Shattuck Labs beats Korro Bio on 13 of the 17 factors compared between the two stocks.

How does Korro Bio compare to BridgeBio Oncology Therapeutics?

BridgeBio Oncology Therapeutics (NASDAQ:BBOT) and Korro Bio (NASDAQ:KRRO) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their dividends, institutional ownership, valuation, media sentiment, earnings, analyst recommendations, profitability and risk.

BridgeBio Oncology Therapeutics has a net margin of 0.00% compared to Korro Bio's net margin of -1,834.48%. BridgeBio Oncology Therapeutics' return on equity of -46.90% beat Korro Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BridgeBio Oncology Therapeutics	N/A	-46.90%	-42.17%
Korro Bio	-1,834.48%	-114.26%	-68.57%

BridgeBio Oncology Therapeutics presently has a consensus price target of $24.40, indicating a potential upside of 185.71%. Korro Bio has a consensus price target of $16.71, indicating a potential upside of 32.97%. Given BridgeBio Oncology Therapeutics' higher possible upside, analysts clearly believe BridgeBio Oncology Therapeutics is more favorable than Korro Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BridgeBio Oncology Therapeutics	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.75
Korro Bio	1 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	3 Strong Buy rating(s)	2.92

BridgeBio Oncology Therapeutics has a beta of 0.35, meaning that its stock price is 65% less volatile than the broader market. Comparatively, Korro Bio has a beta of 3.04, meaning that its stock price is 204% more volatile than the broader market.

In the previous week, Korro Bio had 6 more articles in the media than BridgeBio Oncology Therapeutics. MarketBeat recorded 7 mentions for Korro Bio and 1 mentions for BridgeBio Oncology Therapeutics. BridgeBio Oncology Therapeutics' average media sentiment score of 0.93 beat Korro Bio's score of 0.77 indicating that BridgeBio Oncology Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
BridgeBio Oncology Therapeutics	Positive
Korro Bio	Positive

54.9% of BridgeBio Oncology Therapeutics shares are held by institutional investors. Comparatively, 13.2% of Korro Bio shares are held by institutional investors. 24.4% of BridgeBio Oncology Therapeutics shares are held by insiders. Comparatively, 4.8% of Korro Bio shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Korro Bio has higher revenue and earnings than BridgeBio Oncology Therapeutics. BridgeBio Oncology Therapeutics is trading at a lower price-to-earnings ratio than Korro Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BridgeBio Oncology Therapeutics	N/A	N/A	-$134.04M	-$2.76	N/A
Korro Bio	$6.39M	28.98	-$117.26M	-$10.00	N/A

Summary

BridgeBio Oncology Therapeutics beats Korro Bio on 9 of the 16 factors compared between the two stocks.

How does Korro Bio compare to Allogene Therapeutics?

Allogene Therapeutics (NASDAQ:ALLO) and Korro Bio (NASDAQ:KRRO) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, earnings, analyst recommendations, institutional ownership, profitability, dividends, media sentiment and valuation.

Allogene Therapeutics has a beta of 0.48, meaning that its stock price is 52% less volatile than the broader market. Comparatively, Korro Bio has a beta of 3.04, meaning that its stock price is 204% more volatile than the broader market.

In the previous week, Allogene Therapeutics had 6 more articles in the media than Korro Bio. MarketBeat recorded 13 mentions for Allogene Therapeutics and 7 mentions for Korro Bio. Allogene Therapeutics' average media sentiment score of 0.92 beat Korro Bio's score of 0.77 indicating that Allogene Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Allogene Therapeutics	6 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Korro Bio	3 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

83.6% of Allogene Therapeutics shares are owned by institutional investors. Comparatively, 13.2% of Korro Bio shares are owned by institutional investors. 13.2% of Allogene Therapeutics shares are owned by insiders. Comparatively, 4.8% of Korro Bio shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Allogene Therapeutics has a net margin of 0.00% compared to Korro Bio's net margin of -1,834.48%. Allogene Therapeutics' return on equity of -50.04% beat Korro Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Allogene Therapeutics	N/A	-50.04%	-36.74%
Korro Bio	-1,834.48%	-114.26%	-68.57%

Allogene Therapeutics presently has a consensus price target of $8.30, suggesting a potential upside of 318.14%. Korro Bio has a consensus price target of $16.71, suggesting a potential upside of 32.97%. Given Allogene Therapeutics' higher possible upside, research analysts plainly believe Allogene Therapeutics is more favorable than Korro Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Allogene Therapeutics	1 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.69
Korro Bio	1 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	3 Strong Buy rating(s)	2.92

Korro Bio has higher revenue and earnings than Allogene Therapeutics. Allogene Therapeutics is trading at a lower price-to-earnings ratio than Korro Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Allogene Therapeutics	$20K	34,289.88	-$190.89M	-$0.67	N/A
Korro Bio	$6.39M	28.98	-$117.26M	-$10.00	N/A

Summary

Allogene Therapeutics beats Korro Bio on 11 of the 17 factors compared between the two stocks.

How does Korro Bio compare to Monopar Therapeutics?

Monopar Therapeutics (NASDAQ:MNPR) and Korro Bio (NASDAQ:KRRO) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their analyst recommendations, profitability, media sentiment, institutional ownership, risk, valuation, earnings and dividends.

Monopar Therapeutics has a beta of 1.47, meaning that its share price is 47% more volatile than the broader market. Comparatively, Korro Bio has a beta of 3.04, meaning that its share price is 204% more volatile than the broader market.

Monopar Therapeutics presently has a consensus target price of $118.67, suggesting a potential upside of 9.18%. Korro Bio has a consensus target price of $16.71, suggesting a potential upside of 32.97%. Given Korro Bio's stronger consensus rating and higher probable upside, analysts clearly believe Korro Bio is more favorable than Monopar Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Monopar Therapeutics	1 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	2 Strong Buy rating(s)	2.86
Korro Bio	1 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	3 Strong Buy rating(s)	2.92

Monopar Therapeutics has a net margin of 0.00% compared to Korro Bio's net margin of -1,834.48%. Monopar Therapeutics' return on equity of -13.08% beat Korro Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Monopar Therapeutics	N/A	-13.08%	-12.79%
Korro Bio	-1,834.48%	-114.26%	-68.57%

1.8% of Monopar Therapeutics shares are held by institutional investors. Comparatively, 13.2% of Korro Bio shares are held by institutional investors. 9.7% of Monopar Therapeutics shares are held by insiders. Comparatively, 4.8% of Korro Bio shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Monopar Therapeutics has higher earnings, but lower revenue than Korro Bio. Monopar Therapeutics is trading at a lower price-to-earnings ratio than Korro Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Monopar Therapeutics	N/A	N/A	-$13.72M	-$2.17	N/A
Korro Bio	$6.39M	28.98	-$117.26M	-$10.00	N/A

In the previous week, Monopar Therapeutics and Monopar Therapeutics both had 7 articles in the media. Korro Bio's average media sentiment score of 0.77 beat Monopar Therapeutics' score of 0.56 indicating that Korro Bio is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Monopar Therapeutics	4 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Korro Bio	3 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Korro Bio beats Monopar Therapeutics on 8 of the 15 factors compared between the two stocks.

Get Korro Bio News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding KRRO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

KRRO vs. The Competition

Export

Metric	Korro Bio	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$185.16M	$3.91B	$7.13B	$12.80B
Dividend Yield	N/A	3.61%	2.54%	11.27%
P/E Ratio	-1.26	11.65	272.81	25.43
Price / Sales	28.98	1,394.01	686.32	122.60
Price / Cash	N/A	44.06	28.74	36.03
Price / Book	2.30	16.74	11.02	6.33
Net Income	-$117.26M	-$22.71M	$3.47B	$349.46M
7 Day Performance	-3.83%	2.47%	1.11%	-0.17%
1 Month Performance	21.22%	12.45%	8.03%	4.26%
1 Year Performance	-45.54%	53.62%	23.69%	14.59%

Korro Bio Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
KRRO Korro Bio	2.3675 of 5 stars	$12.57 -2.6%	$16.71 +33.0%	-44.1%	$185.16M	$6.39M	N/A	70
AURA Aura Biosciences	2.8145 of 5 stars	$7.82 -1.0%	$17.50 +123.8%	+18.2%	$810.97M	N/A	N/A	50	Positive News High Trading Volume
STTK Shattuck Labs	3.699 of 5 stars	$8.04 +1.8%	$12.78 +58.9%	+617.8%	$806.89M	$1M	N/A	100	Positive News
BBOT BridgeBio Oncology Therapeutics	2.4905 of 5 stars	$9.37 +2.5%	$24.40 +160.4%	N/A	$751.19M	N/A	N/A	N/A
ALLO Allogene Therapeutics	2.2702 of 5 stars	$2.17 +6.9%	$8.30 +282.5%	+78.8%	$749.71M	$20K	N/A	310

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:KRRO) was last updated on 8/31/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Korro Bio (KRRO) Competitors

KRRO vs. AURA, STTK, BBOT, ALLO, and MNPR

How does Korro Bio compare to Aura Biosciences?

Summary

How does Korro Bio compare to Shattuck Labs?

Summary

How does Korro Bio compare to BridgeBio Oncology Therapeutics?

Summary

How does Korro Bio compare to Allogene Therapeutics?

Summary

How does Korro Bio compare to Monopar Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

KRRO vs. The Competition

Korro Bio Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Korro Bio (KRRO) Competitors

KRRO vs. AURA, STTK, BBOT, ALLO, and MNPR

How does Korro Bio compare to Aura Biosciences?

Which has more volatility & risk, AURA or KRRO?

Which has better valuation & earnings, AURA or KRRO?

Does the media prefer AURA or KRRO?

Do analysts recommend AURA or KRRO?

Do institutionals & insiders hold more shares of AURA or KRRO?

Is AURA or KRRO more profitable?

Summary

How does Korro Bio compare to Shattuck Labs?

Does the media prefer KRRO or STTK?

Do analysts rate KRRO or STTK?

Which has better earnings and valuation, KRRO or STTK?

Is KRRO or STTK more profitable?

Do insiders and institutionals believe in KRRO or STTK?

Which has more risk and volatility, KRRO or STTK?

Summary

How does Korro Bio compare to BridgeBio Oncology Therapeutics?

Is BBOT or KRRO more profitable?

Do analysts recommend BBOT or KRRO?

Which has more risk & volatility, BBOT or KRRO?

Does the media favor BBOT or KRRO?

Do institutionals and insiders believe in BBOT or KRRO?

Which has better earnings and valuation, BBOT or KRRO?

Summary

How does Korro Bio compare to Allogene Therapeutics?

Which has more volatility and risk, ALLO or KRRO?

Does the media favor ALLO or KRRO?

Do institutionals and insiders have more ownership in ALLO or KRRO?

Is ALLO or KRRO more profitable?

Do analysts prefer ALLO or KRRO?

Which has better valuation & earnings, ALLO or KRRO?

Summary

How does Korro Bio compare to Monopar Therapeutics?

Which has more volatility & risk, MNPR or KRRO?

Do analysts rate MNPR or KRRO?

Is MNPR or KRRO more profitable?

Do institutionals & insiders have more ownership in MNPR or KRRO?

Which has higher valuation & earnings, MNPR or KRRO?

Does the media prefer MNPR or KRRO?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

KRRO vs. The Competition

Korro Bio Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools